| Literature DB >> 31653719 |
Masahiko Akamatsu1,2, Norihisa Mikami3,4, Naganari Ohkura3,5, Ryoji Kawakami3, Yohko Kitagawa3, Atsushi Sugimoto3, Keiji Hirota4, Naoto Nakamura2, Satoru Ujihara2, Toshio Kurosaki2, Hisao Hamaguchi2, Hironori Harada2, Guliang Xia6, Yoshiaki Morita1,2, Ichiro Aramori1,2, Shuh Narumiya7, Shimon Sakaguchi8,4.
Abstract
A promising way to restrain hazardous immune responses, such as autoimmune disease and allergy, is to convert disease-mediating T cells into immunosuppressive regulatory T (Treg) cells. Here, we show that chemical inhibition of the cyclin-dependent kinase 8 (CDK8) and CDK19, or knockdown/knockout of the CDK8 or CDK19 gene, is able to induce Foxp3, a key transcription factor controlling Treg cell function, in antigen-stimulated effector/memory as well as naïve CD4+ and CD8+ T cells. The induction was associated with STAT5 activation, independent of TGF-β action, and not affected by inflammatory cytokines. Furthermore, in vivo administration of a newly developed CDK8/19 inhibitor along with antigen immunization generated functionally stable antigen-specific Foxp3+ Treg cells, which effectively suppressed skin contact hypersensitivity and autoimmune disease in animal models. The results indicate that CDK8/19 is physiologically repressing Foxp3 expression in activated conventional T cells and that its pharmacological inhibition enables conversion of antigen-specific effector/memory T cells into Foxp3+ Treg cells for the treatment of various immunological diseases.Entities:
Year: 2019 PMID: 31653719 DOI: 10.1126/sciimmunol.aaw2707
Source DB: PubMed Journal: Sci Immunol ISSN: 2470-9468